Fascinating Inc article: “This Startup Is Growing Mini-Livers to Keep Patients AliveDimension Bio wants to grow a simplified liver from cells to sustain patients long enough for a damaged liver to recover—or until a transplant.”
Summary of the article–
📌 Startup & Mission
- Dimension Bio is a Chicago-based biotech company developing miniature, simplified livers to help sustain patients with severe liver damage until their own liver recovers or until they can receive a transplant.
🧠 Technology & Background
- The company’s founders originally focused on using 3D-printed scaffolds to regenerate bone, gaining FDA clearance for their scaffold technology.
- They repurposed this technology into their BioNidum platform: a 3D-printed scaffold made of PLGA designed to rapidly promote blood vessel in-growth and better integration with host tissue.
👩🔬 How It Works
- The scaffold is seeded with liver cells (from donors or derived from stem cells) and implanted under the skin to form a small, functional tissue that supplements liver function.
- In animal studies, such mini-livers have increased survival rates by >70% in models of liver damage, though human versions will require billions of cells.
🎯 Goals & Timeline
- The goal is not a full liver replacement but a temporary support organ.
- Dimension Bio is targeting human clinical trials by ~2028 following further testing in rats and pigs.
💡 Company Context
- The pivot reflects the huge unmet need in liver failure care given high mortality rates and transplant shortages.
- The company has raised seed and Series A funding (~$20.5M) and is planning further investment rounds.